1. Home
  2. FRO vs PTCT Comparison

FRO vs PTCT Comparison

Compare FRO & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Frontline Plc

FRO

Frontline Plc

HOLD

Current Price

$37.11

Market Cap

4.8B

ML Signal

HOLD

Logo PTC Therapeutics Inc.

PTCT

PTC Therapeutics Inc.

HOLD

Current Price

$68.55

Market Cap

5.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRO
PTCT
Founded
1985
1998
Country
Cyprus
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.8B
5.7B
IPO Year
1995
2006

Fundamental Metrics

Financial Performance
Metric
FRO
PTCT
Price
$37.11
$68.55
Analyst Decision
Strong Buy
Buy
Analyst Count
3
17
Target Price
$37.67
$80.65
AVG Volume (30 Days)
2.1M
1.4M
Earning Date
05-22-2026
05-07-2026
Dividend Yield
4.85%
N/A
EPS Growth
N/A
264.48
EPS
N/A
N/A
Revenue
N/A
$264,734,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$17.70
P/E Ratio
$34.05
N/A
Revenue Growth
N/A
36.19
52 Week Low
$16.25
$43.18
52 Week High
$39.89
$87.50

Technical Indicators

Market Signals
Indicator
FRO
PTCT
Relative Strength Index (RSI) 50.61 46.49
Support Level $36.11 $62.87
Resistance Level $39.20 $69.23
Average True Range (ATR) 1.33 2.81
MACD -0.10 -0.18
Stochastic Oscillator 27.55 27.41

Price Performance

Historical Comparison
FRO
PTCT

About FRO Frontline Plc

Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.

About PTCT PTC Therapeutics Inc.

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Share on Social Networks: